Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?

International Orthopaedics

Volumn 37, Issue 4, 2013, Pages 583-587

  Brunnekreef, Jaap J ^a   Hoogervorst, Paul ^a   Ploegmakers, Marieke J ^a   Rijnen, Wim H ^a   Schreurs, Berend W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ETORICOXIB;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR SHAFT PERFORATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; HIP RADIOGRAPHY; HUMAN; LUNG EMBOLISM; MALE; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PERFORATION; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYNDROME DELINEATION; TOTAL HIP PROSTHESIS; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIP JOINT; HIP PROSTHESIS; HUMANS; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; OSTEOARTHRITIS, HIP; PROSPECTIVE STUDIES; PYRIDINES; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME;

EID: 84885081496     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-013-1781-0     Document Type: Article

References (20)

1. Neal B, Gray H, MacMahon S, Dunn L (2002) Incidence of heterotopic bone formation after major hip surgery. ANZ J Surg 72(11):808-821
2. Coventry MB, Scanlon PW (1981) The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. J Bone Joint Surg Am 63(2):201-208
3. Fransen M, Neal B (2004) Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 3:CD001160
4. Neal BC, Rodgers A, Clark T, Gray H, Reid IR, Dunn L, MacMahon SW (2000) A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 71(2):122-128
5. Balboni TA, Gobezie R, Mamon HJ (2006) Heterotopic ossification: Pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. Int J Radiat Oncol Biol Phys 65(5):1289-1299
6. Blokhuis TJ, Frolke JP (2009) Is radiation superior to indomethacin to prevent heterotopic ossification in acetabular fractures?: a systematic review. Clin Orthop Relat Res 467(2):526-530
7. Burd TA, Hughes MS, Anglen JO (2003) Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 85(5):700-705
8. Cella JP, Salvati EA, Sculco TP (1988) Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 3(3):229-234
9. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 98(8):1725-1733
10. Xue D, Zheng Q, Li H, Qian S, Zhang B, Pan Z (2009) Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials. Int Orthop 35(1):3-8
11. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr (1973) Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 55(8):1629-1632
12. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
13. van der Heide HJ, Koorevaar RC, Lemmens JA, van Kampen A, Schreurs BW (2007) Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 127(7):557-561
14. van der Heide HJ, Rijnberg WJ, Van Sorge A, Van Kampen A, Schreurs BW (2007) Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthop 78(1):90-94
15. van der Heide HJ, Koorevaar RT, Schreurs BW, van Kampen A, Lemmens A (1999) Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplasty 14(7):796-799
16. Renner B, Walter G, Strauss J, Fromm MF, Zacher J, Brune K (2012) Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief. Eur J Pain 16(6):838-848
17. Macfarlane RJ, Ng BH, Gamie Z, El Masry MA, Velonis S, Schizas C, Tsiridis E (2008) Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother 9(5):767-786
18. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102
19. Weir MR, Sperling RS, Reicin A, Gertz BJ (2003) Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146(4):591-604
20. Weber EW, Slappendel R, Durieux ME, Dirksen R, van der Heide H, Spruit M (2003) COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol 20(12):963-966